{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:02:38Z","timestamp":1777899758971,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01579-8","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T02:12:40Z","timestamp":1756692760000},"page":"915-923","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of semi-dose venetoclax plus azacitidine in unfit acute myeloid leukemia patients in China: a real-world single-center study"],"prefix":"10.1007","volume":"43","author":[{"given":"Xian","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Yi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi-Bin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Bin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"1579_CR1","first-page":"38","volume":"103","author":"A Pelcovits","year":"2020","unstructured":"Pelcovits A, Niroula R (2020) Acute myeloid leukemia: a review. R I Med J 103:38\u201340","journal-title":"R I Med J"},{"key":"1579_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10238-024-01536-4","volume":"25","author":"X Han","year":"2025","unstructured":"Han X, Liu X, Wan K, Yan H, Zhang M, Liu H, Gao L, Gao L, Zhang C, Wen Q et al (2025) The clinical features and outcomes of elderly patients with acute myeloid leukemia: a real word research. Clin Exp Med 25:27. https:\/\/doi.org\/10.1007\/s10238-024-01536-4","journal-title":"Clin Exp Med"},{"key":"1579_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752","journal-title":"Blood"},{"key":"1579_CR4","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, D\u00f6hner H, Letai A, Fenaux P et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"1579_CR5","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1186\/s12885-025-14167-z","volume":"25","author":"JF Bai","year":"2025","unstructured":"Bai JF, Wang T, Li JT, Zhang CL, Qian L, Yang YZ, Yun XY, Yin JJ, Zhao F, Ding WD et al (2025) Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center study. BMC Cancer 25:990. https:\/\/doi.org\/10.1186\/s12885-025-14167-z","journal-title":"BMC Cancer"},{"key":"1579_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/hon.2964","volume":"40","author":"D Brackman","year":"2022","unstructured":"Brackman D, Eckert D, Menon R, Salem AH, Potluri J, Smith BD, Wei AH, Hayslip J, Miles D, Mensing S et al (2022) Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-na\u00efve acute myeloid leukemia who are ineligible for intensive chemotherapy. Hematol Oncol 40:269\u2013279. https:\/\/doi.org\/10.1002\/hon.2964","journal-title":"Hematol Oncol"},{"key":"1579_CR7","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/jcph.2248","volume":"63","author":"JQX Gong","year":"2023","unstructured":"Gong JQX, Suleiman AA, Menon R, Deng R, Mensing S, Salem AH (2023) Pooled population pharmacokinetic analyses of venetoclax in patients across indications and healthy subjects from phase 1, 2, and 3 clinical trials. J Clin Pharmacol 63:950\u2013960. https:\/\/doi.org\/10.1002\/jcph.2248","journal-title":"J Clin Pharmacol"},{"key":"1579_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41408-025-01269-x","volume":"15","author":"C Willekens","year":"2025","unstructured":"Willekens C, Bazinet A, Chraibi S, Bataller A, Decroocq J, Arani N, Carpentier B, Rausch C, Lebon D, Maiti A et al (2025) Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood Cancer J 15:68. https:\/\/doi.org\/10.1038\/s41408-025-01269-x","journal-title":"Blood Cancer J"},{"key":"1579_CR9","unstructured":"National Comprehensive Cancer Network (NCCN) (2025) NCCN Clinical practice guidelines in oncology: acute myeloid leukemia. Version 3.2025. National Comprehensive Cancer Network. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf.\u00a0Accessed 28 Jun 2025"},{"key":"1579_CR10","doi-asserted-by":"publisher","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia 36:1703\u20131719.  https:\/\/doi.org\/10.1038\/s41375-022-01613-1","DOI":"10.1038\/s41375-022-01613-1"},{"key":"1579_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"1579_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A (2021) Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr 112:90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009","journal-title":"Actas Dermosifiliogr"},{"key":"1579_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101317","volume":"101317","author":"B Krayem","year":"2025","unstructured":"Krayem B, Frisch A, Horowitz N (2025) Novel therapies for acute myeloid leukemia. Does age still matter? Blood Rev 101317:101317. https:\/\/doi.org\/10.1016\/j.blre.2025.101317","journal-title":"Blood Rev"},{"key":"1579_CR14","doi-asserted-by":"publisher","unstructured":"Nagel G, Weber D, Fromm E, Erhardt S, L\u00fcbbert M, Fiedler W, Kindler T, Krauter J, Brossart P, K\u00fcndgen A, German-Austrian AML Study Group (AMLSG) et al (2017) Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol 96:1993\u20132003. https:\/\/doi.org\/10.1007\/s00277-017-3150-3","DOI":"10.1007\/s00277-017-3150-3"},{"key":"1579_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3238\/arztebl.2011.0863","volume":"108","author":"U Krug","year":"2011","unstructured":"Krug U, B\u00fcchner T, Berdel WE, M\u00fcller-Tidow C (2011) The treatment of elderly patients with acute myeloid leukemia. Dtsch Arztebl Int 108:863\u2013870. https:\/\/doi.org\/10.3238\/arztebl.2011.0863","journal-title":"Dtsch Arztebl Int"},{"key":"1579_CR16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","volume":"132","author":"M Konopleva","year":"2018","unstructured":"Konopleva M, Letai A (2018) BCL-2 inhibition in AML: an unexpected bonus? Blood 132:1007\u20131012. https:\/\/doi.org\/10.1182\/blood-2018-03-828269","journal-title":"Blood"},{"key":"1579_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, Konopleva M, Thirman MJ, Arellano M, Becker PS et al (2021) Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol 96:208\u2013217. https:\/\/doi.org\/10.1002\/ajh.26039","journal-title":"Am J Hematol"},{"key":"1579_CR18","doi-asserted-by":"publisher","unstructured":"Todisco E, Papayannidis C, Fracchiolla N, Petracci E, Zingaretti C, Vetro C, Martelli MP, Zappasodi P, Di Renzo N, Gallo S et al (2023) AVALON Cooperative Group. AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed\/refractory patients with acute myeloid leukemia. Cancer 129:992\u20131004. https:\/\/doi.org\/10.1002\/cncr.34608","DOI":"10.1002\/cncr.34608"},{"key":"1579_CR19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00277-023-05109-5","volume":"102","author":"AM Zeidan","year":"2023","unstructured":"Zeidan AM, Pollyea DA, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M et al (2023) Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Ann Hematol 102:749\u2013754. https:\/\/doi.org\/10.1007\/s00277-023-05109-5","journal-title":"Ann Hematol"},{"key":"1579_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111232","volume":"127","author":"H Yu","year":"2023","unstructured":"Yu H, Wang C, Lei Y, Li L, Wang H, Wang G, Xing L, Guan J, Song J, Wu Y et al (2023) Single-institution experience of venetoclax combined with azacitidine in newly diagnosed acute myeloid leukemia patients. Int Immunopharmacol 127:111232. https:\/\/doi.org\/10.1016\/j.intimp.2023.111232","journal-title":"Int Immunopharmacol"},{"key":"1579_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/ajh.27138","volume":"99","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH et al (2024) Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: genotype signatures for response and survival among 301 consecutive patients. Am J Hematol 99:193\u2013202. https:\/\/doi.org\/10.1002\/ajh.27138","journal-title":"Am J Hematol"},{"key":"1579_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41408-022-00672-y","volume":"12","author":"N Gangat","year":"2022","unstructured":"Gangat N, Tefferi A (2022) To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia. Blood Cancer J 12:75. https:\/\/doi.org\/10.1038\/s41408-022-00672-y","journal-title":"Blood Cancer J"},{"key":"1579_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126:291\u2013299. https:\/\/doi.org\/10.1182\/blood-2015-01-621664","journal-title":"Blood"},{"key":"1579_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cpdd.395","volume":"7","author":"TT Cheung","year":"2018","unstructured":"Cheung TT, Salem AH, Menon RM, Munasinghe WP, Bueno OF, Agarwal SK (2018) Pharmacokinetics of the BCL-2 inhibitor venetoclax in healthy Chinese subjects. Clin Pharmacol Drug Dev 7:435\u2013440. https:\/\/doi.org\/10.1002\/cpdd.395","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1579_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, Thijssen R, Pomilio G, Ivey A, Salmon JM et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135:791\u2013803. https:\/\/doi.org\/10.1182\/blood.2019003988","journal-title":"Blood"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01579-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01579-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01579-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:03:02Z","timestamp":1760194982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01579-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1579"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01579-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines and was approved by the ethics committee of the Second Affiliated Hospital of Zhejiang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent for participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The subjects gave written informed consent for the publication of any associated data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}